Bibliographic Details
| Title: |
Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer |
| Authors: |
Zhang, Zhenchao, Luo, Rui, Kelly, William K., Chen, Joshua, Donahue, Shane, Ip, Kevan, Handley, Nathan R., Tester, William J., Tsang, Miranda L., Kim, Felix J., Myers, Ronald, Lu-Yao, Grace, Gu, Jian, Lin, Jianqing, Li, Bingshan, Wang, Chun, Yang, Hushan |
| Source: |
Prostate Cancer and Prostatic Diseases; 20230101, Issue: Preprints p1-9, 9p |
| Abstract: |
Background: Identification of emerging molecular biomarkers on circulating tumor cells (CTCs) represents an attractive feature of liquid biopsy that facilitates precision and tailored medicine in the management of metastatic castration-resistant prostate cancer (mCRPC). Prostein is an androgen-regulated transmembrane protein with high prostate specificity. Prostein-positive circulating tumor cell (CTC) was recently suggested to have diagnostic potential; however, no study has been conducted to evaluate its prognostic value in mCRPC. Methods: CTCs from mCRPC patients were enumerated using the CellSearch System. Prostein-positive CTCs were identified by immunostaining results. The relationships between prostein expression on CTCs and PSA response rate, PSA progression-free survival (PSA-PFS), radiographic progression-free survival (PFS), and overall survival (OS) were tested by Fisher’s exact test or evaluated using Kaplan–Meier and multivariate Cox analyses. Results: Prostein-positive CTCs were identified in 31 of 87 baseline samples from mCRPC patients and 16 of 51 samples collected at the first follow-up visit. PSA response rates were significantly lower in baseline prostein-positive patients (0%, 0/31) than in prostein-negative patients (19.6%, 11/56) (p= 0.007). The 31 prostein-positive patients had significantly shorter PSA-PFS (p< 0.001), radiographic PFS (p< 0.001), and OS (p= 0.018), compared to the 56 prostein-negative patients at baseline. The association with PSA-PFS maintained its significance (p= 0.028) in multivariate analyses. Analyzing prostein expression at the first follow-up as well as the conversion of prostein expression from baseline to follow-up samples not only confirmed the association with PSA-PFS, but also demonstrated prognostic significance with OS. Conclusion: Our study provides the first evidence to support the potential of prostein expression on CTCs to serve as a novel prognostic marker in mCRPC patients. Future large-scale prospective studies are needed to validate our findings. |
| Database: |
Supplemental Index |
